ClinicalTrials.gg
CompletedNCT05680155Updated Sep 10, 2025

A Phase 3 Study to Evaluate the Efficacy of XW003 Compared With Placebo in T2DM Patients

A Phase 3 interventional study of Ecnoglutide and Placebo in T2DM and Type 2 Diabetes Mellitus, sponsored by Hangzhou Sciwind Biosciences Co., Ltd.. Completed at 1 site in China. Open to participants aged 18 Years to 75 Years. Per ClinicalTrials.gov, last updated 2025-09-10.

Sponsored by Hangzhou Sciwind Biosciences Co., Ltd. · Phase 3, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 3
Study type
Interventional
Enrollment
211
Allocation
Randomized
Ages
18 Years to 75 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-16

Among 909 studies in Diabetes Mellitus, Type 2 with a site in China — 205 open to participants now, 228 under way, 46 of them phase 3. Diabetes Mellitus, Type 2 · China.

Enrollment
354th of 767
211 · median 199
Started
2022
with 65 others
Phase 3
207 of 909
38 open now
Registered
566th of 909
by date

Among the 909 studies in Diabetes Mellitus, Type 2 with a site in China, this one is the 354th largest by enrollment of the 767 interventional ones that give a count, is one of 66 that started in 2022, is one of 207 in phase 3, and was the 566th registered.

Diabetes Mellitus, Type 2

10,386 studies on the registry are indexed under Diabetes Mellitus, Type 2; 1,411 are open to participants now.

Browse Diabetes Mellitus, Type 2 studies →

Open to participants now

205 of the 909 studies in Diabetes Mellitus, Type 2 with a site in China are open now. Recruiting first, the newest first:

200 more — sign in →

All 205 open studies →

A study can be open while its sites in China have not opened yet or have stopped. Only those recruiting at a site in China →

Who these studies take

Of the 883 Diabetes Mellitus, Type 2 studies recruiting now, 374 (42%) set no upper age limit and 383 (43%) stop at 75 or younger; 52 take children under 18; 205 take healthy volunteers.

This study: 18 Years to 75 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 909 studies in Diabetes Mellitus, Type 2 with a site in China, or all of them as a file.
02

Study summary

The main purpose of this study is to investigate the efficacy and safety of XW003 versus placebo in patients with type 2 diabetes mellitus (T2DM) inadequately controlled by diet and exercise alone

Read the detailed description

In this Phase 3 study, eligible participants will be randomized in a 2:2:1:1 ratio to receive once-weekly subcutaneous XW003 (high or low dose) or volume matching placebo as an adjunct to lifestyle intervention for 24 weeks. The core treatment phase will be followed by a 28-week open-label period where all participants receive XW003.

03

Conditions studied

  • T2DM
  • Type 2 Diabetes Mellitus

Keywords

  • T2DM
  • Glucagon-like peptide-1
  • Ecnoglutide
  • XW003
  • GLP-1
04

Who can participate

Ages eligible
18 Years to 75 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  1. Ability and willingness to participate in the study, give written , and comply with the study specific requirements and all protocol procedures.
  2. Sex: male or female; Age: 18 to 75 years, inclusive
  3. : 20.0 kg/m\^2 to 35.0 kg/m\^2, inclusive
  4. Have been diagnosed with T2DMthat is inadequately controlled with at least 3 months of diet and exercise prior to screening.
  5. ranging from 7.5% to 11.0% at screening, inclusive
  6. FPG ≤13.9 mmol/L at screening.

Exclusion criteria

Exclusion Criteria:

  1. History of type 1 or other types of diabetes mellitus.
  2. Use of any GLP-1 analogue during the 3 months preceding to screening.
  3. History of proliferative diabetic retinopathy, diabetic maculopathy, diabetic neuropathy, or diabetic foot during the 6 months preceding screening.
  4. History of acute or chronic pancreatitis or high risk factors for pancreatitis.
  5. Personal or family history of medullary thyroid carcinoma or multiple endocrine neoplasia syndrome type 2.
  6. History of stomach surgeries or disorders associated with slowed emptying of the stomach during the past 6 months.
  7. History of heart attack, stroke, or congestive heart failure of Grade 3 or 4 in the past 6 months.
Terms in these criteria, in plain language(3)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

BMI (body mass index)

Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.

What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.

HbA1c

A blood test of average blood sugar over the past two to three months, given as a percentage or in mmol/mol. 6.5% (48 mmol/mol) or more is the usual threshold for diabetes, normally confirmed by a second test.

05

Study design

Phase
Phase 3
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Double (Participant, Investigator)
Enrollment
211 participants (actual)

Study arms

  • Experimental
    C1-XW003

    High dosage of XW003 once weekly

    Drug: Ecnoglutide

  • Placebo comparator
    C1-Placebo

    Matched Placebo once weekly

    Drug: Placebo

  • Experimental
    C2-XW003

    Low dosage of XW003 once weekly

    Drug: Ecnoglutide

  • Placebo comparator
    C2-Placebo

    Matched Placebo once weekly

    Drug: Placebo

Interventions

  • Subcutaneous Injection

    Also known as: XW003

  • DrugPlacebo

    Subcutaneous Injection with matched volume

06

What researchers measure

Primary outcomes

  1. Change from baseline in HbA1c

    Time frame: Baseline, Week 24

Secondary outcomes

  1. Change from baseline in HbA1c

    Time frame: Baseline, Week 5, Week 9, Week 13, Week 17, Week 29, Week 33, Week 37, Week 45, Week 52

  2. Proportion of subjects with HbA1c < 7% and HbA1c ≤6.5% after treatment

    Time frame: week 24, week 52

  3. Proportion of subjects with HbA1c < 7%, with no severe hypoglycemia or no weight gain

    Time frame: week 24

  4. Change from baseline in fasting plasma glucose (FPG)

    Time frame: Baseline, Week 24 and Week 52

  5. Change from baseline in fasting insulin

    Time frame: Baseline, Week 24 and Week 52

  6. Change from baseline in lipid panel

    Time frame: Baseline, Week 24 and Week 52

  7. Change from baseline in 2-hour postprandial blood glucose

    Time frame: Baseline, Week 24 and Week 52

  8. Change from baseline in 7-point self-monitored blood glucose

    Time frame: Baseline, Week 24 and Week 52

  9. Change from baseline in HOMA-IR

    Time frame: Baseline, Week 24 and Week 52

  10. Change from baseline in HOMA-β

    Time frame: Baseline, Week 24 and Week 52

  11. Change from baseline in body weight

    Time frame: Baseline, Week 24 and Week 52

  12. Change from baseline in waist circumference

    Time frame: Baseline, Week 24 and Week 52

  13. Change from baseline in hip circumference

    Time frame: Baseline, Week 24 and Week 52

Other outcomes

  1. Incidence of adverse events

    Time frame: from baseline to EOS

  2. Pharmacokinetics: plasma trough level of XW003

    Time frame: Baseline, D29, D57, D85, D168, D197, D225, D253, D364, D399

  3. Immunogenecity of XW003

    Time frame: Baseline, D85, D168, D253, D399

07

Study locations

1 site
  • Nanjing Drum Tower Hospital
    Nanjing, Jiangsu 210008, China
08

References and documents

Publications

  • Zhu D, Wang W, Tong G, Ma J, Wen B, Zheng X, Shi B, Pang S, Wang K, Shi X, Zhang X, Fu L, Liu Y, Lu Y, Huang D, Jiang C, Pan T, Xue H, Han J, Ding H, Bing S, Jiang F, Zheng Q, Yang M, Guan L, Liu X, Ning J, Bu Y, Guo M, Yang L, Guo W, Li Y, Xu S, Pan H. Efficacy and safety of cAMP signalling-biased GLP-1 analogue ecnoglutide monotherapy versus placebo in patients with type 2 diabetes (EECOH-1): a multi-centre, randomised, double-blind, placebo-controlled, phase 3 trial. Nat Commun. 2026 Jan 7;17(1):1420. doi: 10.1038/s41467-025-68165-7. PubMed 41501026 ↗

Individual participant data

Plan to share: No

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Ran from Dec 2022 to primary completion in Jun 2024, 17 months.

Of 438 industry-sponsored phase 3 interventional studies under Diabetes Mellitus, Type 2, half reached primary completion within 19 months of starting (the median), counting those still running; a quarter within 14 and three quarters within 26. This study's 17 months is below that.

Counting every sponsor, half of 525 studies reached it within 20 months; a quarter within 14 and three quarters within 30.

How these figures are worked out, and which studies are left out of them.

Registered
Dec 25, 2022
First posted
Jan 11, 2023
StartActual
Dec 29, 2022
Primary completionActual
Jun 12, 2024
CompletionActual
Oct 12, 2024
Last update
Sep 10, 2025
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Sep 10, 2025, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT05680155
Lead sponsor
Hangzhou Sciwind Biosciences Co., Ltd.
Responsible party
Sponsor
First posted
Jan 11, 2023
Start date
Dec 29, 2022
Primary completion
Jun 12, 2024
Completion
Oct 12, 2024
Last update
Sep 10, 2025

Study contacts

Dalong Zhu
principal investigator · The Affiliated Nanjing Drum Tower Hospital of Nanjing University Medical School

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Jul 2023. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Ecnoglutide

Start the discussion